MetaCap

ImmunityBio (IBRX) vs Scholar Rock (SRRK)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

ImmunityBio (IBRX) has outperformed Scholar Rock (SRRK) over the past year, gaining 189.4% versus a gain of 19.7%. Over five years, SRRK leads with a +78.5% price change compared with -7.4% for IBRX. ImmunityBio is the larger company by market cap ($6.40 billion vs $5.87 billion), about 1.1 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

IBRX+189.42%SRRK+19.70%
+478%+225%-28%
Nov 21, 20251 yearNov 20, 2026
IBRX-6.38%SRRK+62.93%
+105%+6%-92%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

IBRX versus SRRK key metrics
MetricIBRXSRRK
Share price$6.02$48.13
Market cap$6.40B$5.87B
1-day change-8.37%-4.45%
YTD return+204.04%+9.26%
1-year return+189.42%+19.70%
5-year return-7.38%+78.46%
EPS (TTM)$-1.06$-3.23
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$113.29M$0
Revenue growth (YoY)+668.31%—
Net income (latest FY)$-351.40M$-377.94M
Gross margin99.34%—
Operating margin-226.00%—
Net margin-310.18%—
52-week high$12.43$61.76
52-week low$1.95$38.69
Distance from 52-week high-51.57%-22.07%
Analyst consensusstrong_buystrong_buy
Avg. price target upside+136.71%+45.56%
Average volume12.97M1.86M
Shares outstanding1.06B122.00M
Employees684289
SectorHealth CareHealth Care
IndustryBiotechnology: Biological Products (No Diagnostic Substances)Biotechnology: Biological Products (No Diagnostic Substances)

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • IBRX has outperformed SRRK by 169.7 percentage points over the past year.

About ImmunityBio

IBRX stock →

ImmunityBio, Inc., a biotechnology company, focuses on innovating, developing, and commercializing next-generation immunotherapies designed to activate the patient's immune system and deliver durable protection against cancer and infectious diseases. Its platforms for the development of biologic products and product candidates that include cytokine fusion proteins, DNA and vaccine vectors, and cell therapies.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 684 employees

About Scholar Rock

SRRK stock →

Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on improving the lives of children and adults with spinal muscular atrophy (SMA) and other rare, severe, and debilitating neuromuscular diseases. The company's novel understanding of the molecular mechanisms of growth factor activation within the transforming growth factor beta (TGFß) superfamily has enabled the development of a proprietary platform.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 289 employees

IBRX vs SRRK FAQ

Which is bigger, ImmunityBio or Scholar Rock?

ImmunityBio (IBRX) is larger, with a market capitalization of $6.40B compared with $5.87B for Scholar Rock (SRRK).

Which stock has performed better over the past year, IBRX or SRRK?

IBRX returned +189.42% over the past 12 months, compared with +19.70% for SRRK (price return, excluding dividends). Past performance does not predict future results.

Are ImmunityBio and Scholar Rock in the same industry?

Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.

More comparisons